NicholaosCBellosMDFIDSA FACP(He/Him)
Infectious Disease • Dallas, TXMedical Director Diagnostic Services Quest Laboratories
Dr. Bellos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2603 Oak Lawn Ave
Ste 500
Dallas, TX 75219Phone+1 214-396-4201Fax+1 469-453-3335
Education & Training
University of Miami/Jackson Health SystemFellowship, Infectious Disease, 1987 - 1989
Tulane UniversityResidency, Internal Medicine, 1983 - 1987
Baylor College of MedicineClass of 1981
Certifications & Licensure
TX State Medical License 1982 - 2026
FL State Medical License 1987 - 2025
OK State Medical License 2014 - 2015
LA State Medical License 1984 - 1987- American Board of Internal Medicine Internal Medicine
Clinical Trials
- BLADE: Comparison of Once Daily Lopinavir/Ritonavir to Lopinavir/Ritonavir BID Dosing in HIV-Infected Subjects
- Bavituximab Repeat-Dose Trial in Patients Co-Infected With Chronic Hepatitis C Virus and Human Immunodeficiency Virus Start of enrollment: 2007 Jul 01
- Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients Start of enrollment: 2012 Jul 01
Publications & Presentations
PubMed
- 171 citationsRandomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.Kimberly Y. Smith, Parul Patel, Derek M. Fine, Nicholaos C. Bellos, Louis Sloan
AIDS. 2009-07-01 - 51 citationsSimilar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine pl...Kathleen Squires, Benjamin Young, Edwin DeJesus, Nicholaos C. Bellos, Daniel Murphy
AIDS. 2010-08-24 - 273 citationsSubgroup analyses of maraviroc in previously treated R5 HIV-1 infection.Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin, Irina Konourina, Andy I. M. Hoepelman
The New England Journal of Medicine. 2008-10-02
Professional Memberships
- Infectious Diseases Society of AmericaFellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
